MetaCap

Exelixis Inc. (EXEL)

NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

64.63-1.20 (-1.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EXEL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$15.77B
52-week range
39.71 – 73.69
Day range
64.45 – 66.94
Volume / Avg
2.19M / 2.45M
Beta
—

52-week range

$39.71$73.69

EXEL stock today

Shares of Exelixis (EXEL) finished lower on Nov 20 at $64.63, a drop of 1.82% or $1.20 per share, versus the S&P 500's 3.70% decline. At this level, EXEL sits in the middle of its 52-week range of $39.71 to $73.69: 12.3% below the high, set on Nov 5, 2026 and 62.8% above the low. EXEL is up 47.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.0%.

At 19.4x trailing earnings, Exelixis trades below the peer-group median of 26.6x. Its forward P/E of 15.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Exelixis

Company profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Michael M. Morrissey Ph.D.
Headquarters
Alameda, CA
Employees
1,077
IPO year
2000

Financial highlights

Full financials

In fiscal 2025, Exelixis generated $2.32 billion in revenue, up 7.0% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $782.6 million (+50.1% year over year), for a net margin of 33.7% versus a median of 11.4% in the prior 5 years. Gross margin was 96.4% (down from 96.5%) and operating margin 37.6%.

Exelixis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B
Growth+6.98%+18.49%+13.60%+12.27%+45.31%
Net income$782.57M$521.27M$207.76M$182.28M$231.06M
EPS (diluted)$2.78$1.76$0.65$0.56$0.72

Analyst forecast

Forecast

Consensus (17 analysts)

buy

Avg. price target

$61.57-4.73%

  • Strong buy 1
  • Buy 5
  • Hold 10
  • Sell 0
  • Strong sell 1

Target range

Low $41.00High $78.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$0.85 vs $0.79
Surprise
+7.59%

EXEL news

All EXEL news

Exelixis peers

Health Care sector
EXEL peer companies
CompanyPrice% ChgMarket capCompare
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs EXEL
BNTXBioNTech SE ADR80.96-0.52%$20.07Bvs EXEL
TECHBio-Techne Corp72.67-0.04%$11.42Bvs EXEL
RGENRepligen Corporation163.81-3.81%$10.47Bvs EXEL
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs EXEL
QGENQiagen N.V.49.30-0.66%$10.18Bvs EXEL
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs EXEL
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs EXEL

Indexes, lists and sector

Exelixis stock FAQ

What is Exelixis's stock price today?

EXEL last traded at $64.63 as of Nov 20, 4:00 PM EST, down 1.82% on the day. Prices are delayed at least 15 minutes.

What is EXEL's P/E ratio?

EXEL trades at a trailing P/E ratio of 19.35 and a forward P/E of 15.12, compared with a median of 26.6 for its closest peers.

Who is Exelixis's CEO?

Dr. Michael M. Morrissey Ph.D. is the chief executive officer of Exelixis Inc., which has about 1,077 employees.

What is the EXEL 52-week high?

The 52-week high for EXEL is $73.69 and the 52-week low is $39.71. The stock is currently 12.3% below its high.

Compare EXEL